Completed PHASE3 INTERVENTIONAL 1-arm NCT01568385

A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) Therapy

Sponsor: Takeda

Interventions TAK-438

Updated 6 times since 2017 Last updated: Feb 7, 2014 Started: Apr 30, 2012 Primary completion: Sep 30, 2013 Completion: Sep 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Duodenal Ulcer and Gastric Ulcer and is currently completed. Takeda leads this study, which shows 6 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Apr 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Takeda

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Annaka-shi, Japan , Fuchu-shi, Japan , Fukuoka, Japan , Funabashi-shi, Japan , Hakodate-shi, Japan , Hiroshima, Japan , Kanazawa, Japan , Katsushika-ku, Japan , Kitahiroshima-shi, Japan , Meguro-ku, Japan and 8 more locations